Labviva, the leading AI procurement platform for life sciences, announced the close of its $25 million Series B, bringing its total funding to ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive results from the Phase 3 C-POST trial, which demonstrated that adjuvant treatment wi...
Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small ...
NORTH CHICAGO, Ill. and SHANGHAI, AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) ann...
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Rev...
As the science of cell and gene therapies (CGT) reaches unprecedented heights, equitable access to these lifesaving treatments must keep pace, said...
BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral dise...
Clinically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1...
Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the expanded commercial availability of the NavDx ...
Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by found...
Andreessen Horowitz (a16z) Bio + Health announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health...
Atropos Health, a pioneer in translating real-world clinical data into real-world evidence (RWE) for decision-making, today announced i...
Bayer announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for KERENDIA® (finerenone...
-Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma announced a strategic partnership to accelerate the development and commercializatio...
© 2025 Biopharma Boardroom. All Rights Reserved.
